<DOC>
	<DOC>NCT00412217</DOC>
	<brief_summary>This two-arm study will compare the efficacy and safety of erlotinib (Tarceva) versus placebo in participants with resected head and neck squamous cell cancer who are receiving concurrent chemoradiotherapy or radiotherapy alone. Participants will be randomized to receive either erlotinib 150 milligrams (mg) orally (PO) once daily or placebo for 1 year until disease progression or unacceptable toxicity.</brief_summary>
	<brief_title>A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults greater than or equal to (â‰¥) 18 years of age Curatively treated head and neck squamous cell cancer with T3T4 and/or N2N3 pathology, with or without other findings of poor prognosis such as extranodal extension, positive resection margins, and perineural or vascular involvement Eastern Cooperative Oncology Group (ECOG) status of 0 to 2 Macroscopic residual disease after surgery Previous treatment with antiepidermal growth factor receptor (antiEGFR) targeted therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>